Rapport Therapeutics, Inc. (RAPP) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 1.43B USD. 52-week range 23.75 to 52.93 USD. Data as of 2026-10-09.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, ...